Fine‐mapping reveals novel alternative splicing of the dopamine transporter

The dopamine transporter gene (SLC6A3, DAT) has been implicated in the pathogenesis of numerous psychiatric and neurodevelopmental disorders, including schizophrenia (SZ). We previously detected association between SZ and intronic SLC6A3 variants that replicated in two independent Caucasian samples, but had no obvious function. In follow‐up analyses, we sequenced the coding and intronic regions of SLC6A3 to identify complete linkage disequilibrium patterns of common variations. We genotyped 78 polymorphisms, narrowing the potentially causal region to two correlated clusters of associated SNPs localized predominantly to introns 3 and 4. Our computational analysis of these intronic regions predicted a novel cassette exon within intron 3, designated E3b, which is conserved among primates. We confirmed alternative splicing of E3b in post‐mortem human substantia nigra (SN). As E3b introduces multiple in‐frame stop codons, the SLC6A3 open reading frame is truncated and the spliced product may undergo nonsense mediated decay. Thus, factors that increase E3b splicing could reduce the amount of unspliced product available for translation. Observations consistent with this prediction were made using cellular assays and in post‐mortem human SN. In mini‐gene constructs, the extent of splicing is also influenced by at least two common haplotypes, so the alternative splicing was evaluated in relation to SZ risk. Meta‐analyses across genome‐wide association studies did not support the initial associations and further post‐mortem studies did not suggest case‐control differences in splicing. These studies do not provide a compelling link to schizophrenia. However, the impact of the alternative splicing on other neuropsychiatric disorders should be investigated. © 2010 Wiley‐Liss, Inc.

[1]  M. Talkowski,et al.  Functional analysis of upstream common polymorphisms of the dopamine transporter gene. , 2010, Schizophrenia bulletin.

[2]  E. Bramon,et al.  Altered effect of dopamine transporter 3'UTR VNTR genotype on prefrontal and striatal function in schizophrenia. , 2009, Archives of general psychiatry.

[3]  P. Visscher,et al.  Common polygenic variation contributes to risk of schizophrenia and bipolar disorder , 2009, Nature.

[4]  Jianxin Shi,et al.  Common variants on chromosome 6p22.1 are associated with schizophrenia , 2009, Nature.

[5]  D. Geschwind,et al.  Functional and Evolutionary Insights into Human Brain Development through Global Transcriptome Analysis , 2009, Neuron.

[6]  Leonardo Fazio,et al.  Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia. , 2009, Brain : a journal of neurology.

[7]  J. Smoller,et al.  Family based association study of pediatric bipolar disorder and the dopamine transporter gene (SLC6A3) , 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[8]  O. Mühlemann,et al.  The meaning of nonsense. , 2008, Trends in cell biology.

[9]  J. Fackenthal,et al.  Aberrant RNA splicing and its functional consequences in cancer cells , 2008, Disease Models & Mechanisms.

[10]  Michael Hiller,et al.  Widespread and subtle: alternative splicing at short-distance tandem sites. , 2008, Trends in genetics : TIG.

[11]  J. Lieberman,et al.  Genomewide association for schizophrenia in the CATIE study: results of stage 1 , 2008, Molecular Psychiatry.

[12]  Michael E Talkowski,et al.  A network of dopaminergic gene variations implicated as risk factors for schizophrenia. , 2008, Human molecular genetics.

[13]  M. Rieder,et al.  The environmental genome project: reference polymorphisms for drug metabolism genes and genome-wide association studies. , 2008, Drug metabolism reviews.

[14]  J. Gádoros,et al.  Dopaminergic candidate genes in Tourette syndrome: Association between tic severity and 3′ UTR polymorphism of the dopamine transporter gene , 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[15]  M. Talkowski,et al.  Dopamine genes and schizophrenia: case closed or evidence pending? , 2007, Schizophrenia bulletin.

[16]  Silke Schmidt,et al.  Interleukin 7 receptor α chain ( IL7R ) shows allelic and functional association with multiple sclerosis , 2007, Nature Genetics.

[17]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[18]  G. Breen,et al.  Dopamine transporter polymorphisms are associated with short-term response to smoking cessation treatment , 2007, Pharmacogenetics and genomics.

[19]  J. Gallant,et al.  RNA-Mediated Neuromuscular Disorders , 2007 .

[20]  E. Fernandez-Egea,et al.  Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait , 2007, Psychopharmacology.

[21]  C. Colosimo,et al.  Dopamine transporter immunoreactivity in peripheral blood lymphocytes discriminates Parkinson’s disease from essential tremor , 2007, Journal of Neural Transmission.

[22]  N. Richtand Behavioral Sensitization, Alternative Splicing, and D3 Dopamine Receptor-Mediated Inhibitory Function , 2006, Neuropsychopharmacology.

[23]  C. Thornton,et al.  RNA-dominant diseases. , 2006, Human molecular genetics.

[24]  J. Lieberman,et al.  Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. , 2006, The American journal of psychiatry.

[25]  R. Murray,et al.  A dopamine transporter gene functional variant associated with cocaine abuse in a Brazilian sample. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[26]  H. Steinhausen Faculty Opinions recommendation of A common haplotype of the dopamine transporter gene associated with attention-deficit/hyperactivity disorder and interacting with maternal use of alcohol during pregnancy. , 2006 .

[27]  T. Sotnikova,et al.  Molecular biology, pharmacology and functional role of the plasma membrane dopamine transporter. , 2006, CNS & neurological disorders drug targets.

[28]  Ravinder Reddy,et al.  Altered Glutathione Redox State in Schizophrenia , 2005, Disease markers.

[29]  David Haussler,et al.  Unusual Intron Conservation near Tissue-Regulated Exons Found by Splicing Microarrays , 2005, PLoS Comput. Biol..

[30]  Gerome Breen,et al.  A common haplotype of the dopamine transporter gene associated with attention-deficit/hyperactivity disorder and interacting with maternal use of alcohol during pregnancy. , 2006, Archives of general psychiatry.

[31]  Nikolaos Koutsouleris,et al.  Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drug–naive schizophrenic patients , 2006, European Archives of Psychiatry and Clinical Neuroscience.

[32]  Ian H. Robertson,et al.  Dissecting the attention deficit hyperactivity disorder (ADHD) phenotype: Sustained attention, response variability and spatial attentional asymmetries in relation to dopamine transporter (DAT1) genotype , 2005, Neuropsychologia.

[33]  H. Vaitkevicius,et al.  Dopamine neurons express multiple isoforms of the nuclear receptor nurr1 with diminished transcriptional activity , 2005, Journal of neurochemistry.

[34]  Nicolas Peyret,et al.  The SNPlex genotyping system: a flexible and scalable platform for SNP genotyping. , 2005, Journal of biomolecular techniques : JBT.

[35]  S. Gabriel,et al.  Efficiency and power in genetic association studies , 2005, Nature Genetics.

[36]  C. Carlson,et al.  Dopamine transporter (SLC6A3) 5′ region haplotypes significantly affect transcriptional activity in vitro but are not associated with Parkinson's disease , 2005, Pharmacogenetics & Genomics.

[37]  L. Maquat,et al.  Mechanistic links between nonsense-mediated mRNA decay and pre-mRNA splicing in mammalian cells. , 2005, Current opinion in cell biology.

[38]  J. Pavía,et al.  Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism , 2005, Psychopharmacology.

[39]  M. Bannon,et al.  Sp1 and Sp3 activate transcription of the human dopamine transporter gene , 2005, Journal of neurochemistry.

[40]  S. Fuke,et al.  Identification and characterization of the Hesr1/Hey1 as a candidate trans-acting factor on gene expression through the 3' non-coding polymorphic region of the human dopamine transporter (DAT1) gene. , 2005, Journal of biochemistry.

[41]  A. Sampson,et al.  Relationship of Brain-Derived Neurotrophic Factor and Its Receptor TrkB to Altered Inhibitory Prefrontal Circuitry in Schizophrenia , 2005, The Journal of Neuroscience.

[42]  D. Kupfer,et al.  Serotonin gene polymorphisms and bipolar I disorder: Focus on the serotonin transporter , 2005, Annals of medicine.

[43]  A. Krainer,et al.  Disruption of exonic splicing enhancer elements is the principal cause of exon skipping associated with seven nonsense or missense alleles of NF1 , 2004, Human mutation.

[44]  G. Hutchins,et al.  Dopamine transporter density in schizophrenic subjects with and without tardive dyskinesia , 2004, Schizophrenia Research.

[45]  P. Chen,et al.  Associated alterations of striatal dopamine D2/D3 receptor and transporter binding in drug-naive patients with schizophrenia: a dual-isotope SPECT study. , 2004, The American journal of psychiatry.

[46]  S. Gallati,et al.  The role of common single‐nucleotide polymorphisms on exon 9 and exon 12 skipping in nonmutated CFTR Alleles , 2004, Human mutation.

[47]  Ivan Nikolov,et al.  Strong evidence for association between the dystrobrevin binding protein 1 gene (DTNBP1) and schizophrenia in 488 parent-offspring trios from Bulgaria , 2004, Biological Psychiatry.

[48]  S. Cragg,et al.  DAncing past the DAT at a DA synapse , 2004, Trends in Neurosciences.

[49]  M. Garcia-Blanco,et al.  Alternative splicing in disease and therapy , 2004, Nature Biotechnology.

[50]  J. Sundsfjord,et al.  123I-β-CIT SPECT demonstrates increased presynaptic dopamine transporter binding sites in basal ganglia in vivo in schizophrenia , 2004, Psychopharmacology.

[51]  D. Black Mechanisms of alternative pre-messenger RNA splicing. , 2003, Annual review of biochemistry.

[52]  Christopher J. Lee,et al.  Alternative splicing in the nervous system: an emerging source of diversity and regulation , 2003, Biological Psychiatry.

[53]  F. Limosin,et al.  The A9 allele of the dopamine transporter gene is associated with delirium tremens and alcohol-withdrawal seizure , 2003, Biological Psychiatry.

[54]  D L Black,et al.  Alternative pre-mRNA splicing and neuronal function. , 2003, Progress in molecular and subcellular biology.

[55]  R. Gainetdinov,et al.  Plasma membrane monoamine transporters: structure, regulation and function , 2003, Nature Reviews Neuroscience.

[56]  T. Sotnikova,et al.  Monoamine transporter pharmacology and mutant mice. , 2002, Trends in pharmacological sciences.

[57]  D. Mash,et al.  Decreased expression of the transcription factor NURR1 in dopamine neurons of cocaine abusers , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[58]  W. Gauderman Sample size requirements for association studies of gene-gene interaction. , 2002, American journal of epidemiology.

[59]  M. Bannon,et al.  The human dopamine transporter gene: gene organization, transcriptional regulation, and potential involvement in neuropsychiatric disorders , 2001, European Neuropsychopharmacology.

[60]  B. Dean,et al.  Studies on dopaminergic and GABAergic markers in striatum reveals a decrease in the dopamine transporter in schizophrenia , 2001, Schizophrenia Research.

[61]  R. Gur,et al.  Striatal dopamine transporters and cognitive functioning in healthy men and women. , 2001, The American journal of psychiatry.

[62]  J. Hietala,et al.  PET studies of brain monoamine transporters. , 2000, Current pharmaceutical design.

[63]  J. Krystal,et al.  Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [123I]β-CIT , 2000, Biological Psychiatry.

[64]  Xin Xu,et al.  Implementing a unified approach to family‐based tests of association , 2000, Genetic epidemiology.

[65]  A. Sampson,et al.  Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. , 1999, The American journal of psychiatry.

[66]  P. Strange,et al.  Comparison of the ability of dopamine receptor agonists to inhibit forskolin-stimulated adenosine 3'5'-cyclic monophosphate (cAMP) accumulation via D2L (long isoform) and D3 receptors expressed in Chinese hamster ovary (CHO) cells. , 1999, Biochemical pharmacology.

[67]  J R O'Connell,et al.  PedCheck: a program for identification of genotype incompatibilities in linkage analysis. , 1998, American journal of human genetics.

[68]  T. Kawarai,et al.  Structure and organization of the gene encoding human dopamine transporter. , 1997, Gene.

[69]  C. Schmauss,et al.  Enhanced Cleavage of an Atypical Intron of Dopamine D3-Receptor Pre-mRNA in Chronic Schizophrenia , 1996, The Journal of Neuroscience.

[70]  J. Kleinman,et al.  Age-related changes in [3H]GBR 12935 binding site density in the prefrontal cortex of controls and schizophrenics , 1995, Biological Psychiatry.

[71]  D. Curtis,et al.  Monte Carlo tests for associations between disease and alleles at highly polymorphic loci , 1995, Annals of human genetics.

[72]  C. Halldin,et al.  Pet study of [11C] β‐CIT binding to monoamine transporters in the monkey and human brain , 1994, Synapse.

[73]  M. Caron,et al.  Molecular characterization of the dopamine transporter. , 1993, Trends in pharmacological sciences.

[74]  S. Amara,et al.  Neurotransmitter transporters: recent progress. , 1993, Annual review of neuroscience.

[75]  X Li,et al.  Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. , 1992, Genomics.

[76]  G. Uhl,et al.  A human dopamine transporter cDNA predicts reduced glycosylation, displays a novel repetitive element and provides racially-dimorphic TaqI RFLPs. , 1992, Brain research. Molecular brain research.

[77]  M. Caron,et al.  Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. , 1992, Molecular pharmacology.

[78]  P. Seeman,et al.  Dopamine receptors and transporters in Parkinson's disease and schizophrenia , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[79]  C. Tanaka,et al.  [3H]GBR-12935 binding sites in human striatal membranes: binding characteristics and changes in parkinsonians and schizophrenics. , 1988, Japanese journal of pharmacology.

[80]  P. Armitage Tests for Linear Trends in Proportions and Frequencies , 1955 .